Factor 8 Gene Roctavian denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for factor 8 gene roctavian are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Roctavian (valoctocogene roxaparvovec) — Experimental / Investigational

Roctavian is an FDA-approved gene therapy for severe hemophilia A in adults. Despite its FDA approval, Cigna may classify Roctavian as "experimental or investigational" if its internal medical policy has not yet been updated to reflect the approval, if its coverage policy requires additional evidence beyond FDA approval (such as long-term outcomes data), or if the specific clinical indication or patient profile falls outside the parameters Cigna has defined as covered.

## Why This Denial Is Appealable

FDA approval is the federal government's determination that a drug or biologic is safe and effective for its indicated use. An insurer's experimental-or-investigational classification of an FDA-approved product is one of the most commonly overturned denial types in external review, because independent reviewers apply the FDA-approved labeling as the baseline standard. If Roctavian is being used within its FDA-approved indication — which you should confirm against the current prescribing label — the experimental classification should not stand. The appeal should lead with the FDA approval date and the indication language from the label.

## Federal Appeal Framework

• Internal appeal: File within 180 days. Request a peer-to-peer review between your hematologist and Cigna's medical director; these often resolve experimental denials faster than written appeals when the FDA approval is clear.
• External review (ACA §2719): After final internal denial, you have approximately four months to request external review. External reviewers have consistently overturned experimental designations for FDA-approved products used within label. This is the strongest lever available.
• ERISA §503: If the plan is employer-sponsored, demand the specific clinical evidence standard Cigna used to classify Roctavian as experimental, and the date Cigna last reviewed its policy.
• Expedited option: If clinical urgency exists, request simultaneous expedited internal and external review.

## Documentation to Gather

1. FDA approval documentation — print the FDA-approved prescribing label, the FDA approval letter, and the FDA product page for Roctavian, showing the approval date and approved indication. 2. Indication matching — confirm in writing (prescriber letter) that the patient's use falls within the FDA-approved indication. Describe the patient's diagnosis and how it matches the labeled indication. 3. Relevant guideline organization acknowledgment — note that the applicable hemophilia treatment guideline organization (e.g., the World Federation of Hemophilia or the relevant national hemophilia society) has addressed gene therapy in its guidance. 4. HTC evaluation records — documentation from a hemophilia treatment center confirming patient candidacy and supporting the treatment plan. 5. Cigna's experimental/investigational policy — obtain and review the specific policy Cigna used, including the criteria it applies to determine whether a treatment is experimental.

## Criteria-Mapping Structure

Build a direct response to each element of Cigna's experimental classification: - Column A: Each criterion Cigna's policy uses to define "experimental" (e.g., FDA approval status, peer-reviewed evidence standard, coverage policy effective date). - Column B: The specific fact that shows the criterion is met or that the classification is inapplicable (FDA approval date, label indication text, HTC letter).

Close with a formal request that Cigna update its coverage policy to reflect FDA approval and re-adjudicate the claim accordingly.